Emergent BioSolutions | EBS - Despesas De Vendas E Administração





Despesas De Vendas E Administração Alterar Data
Acadia Pharmaceuticals USD 146.88M 1.69M 2026-09
Akebia Therapeutics USD 23.53M 3.19M 2025-12
ALKERMES USD 190.54M 6.1M 2026-09
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
Amarin USD 18.97M 1.03M 2025-12
ANI Pharmaceuticals USD 94.86M 3.2M 2026-09
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
Coherus Biosciences USD 15M 6.26M 2025-12
Emergent BioSolutions USD 182.8M 82.3M 2023-06
Exelixis USD 154.56M 6.93M 2026-09
Glaxosmithkline GBP 2.38B 264M 2026-09
Heron Therapeutics USD 23.74M 605K 2025-12
Ionis Pharmaceuticals USD 154M 23.92M 2026-09
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Lexicon Pharmaceuticals USD 3.98M 195K 2025-12
Merck USD 2.86B 25M 2026-09
Moderna USD 282M 66M 2026-09
Myriad Genetics USD 122.3M 6.7M 2025-12
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
Pacira USD 950.8M 858.99M 2026-09
Pfizer USD 3.28B 132M 2026-09
PTC Therapeutics USD 80.63M 6.74M 2026-06
Sanofi EUR 2.31B 325M 2026-09
Sarepta Therapeutics USD 118.61M 11.01M 2026-09
United Therapeutics USD 184.1M 22.6M 2026-09
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12